Open AccessThis article is
- freely available
MicroRNAs and Triple Negative Breast Cancer
Start Up Unit, Experimental Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, Via Amadeo 42, Milan 20133, Italy
* Author to whom correspondence should be addressed.
Received: 2 September 2013; in revised form: 9 October 2013 / Accepted: 11 October 2013 / Published: 11 November 2013
Abstract: Triple Negative Breast Cancer (TNBC) is a very aggressive tumor subtype, which still lacks specific markers for an effective targeted therapy. Despite the common feature of negativity for the three most relevant receptors (ER, PgR and HER2), TNBC is a very heterogeneous disease where different subgroups can be recognized, and both gene and microRNA profiling studies have recently been carried out to dissect the different molecular entities. Moreover, several microRNAs playing a crucial role in triple negative breast cancer biology have been identified, providing the experimental basis for a possible therapeutic application. Indeed, the causal involvement of microRNAs in breast cancer and the possible use of these small noncoding RNA molecules as biomarkers has been extensively studied with promising results. Their application as therapeutic tools might represent an innovative approach, especially for a tumor subgroup still lacking an efficient and specific therapy such as TNBC. In this review, we summarize our knowledge on the most important microRNAs described in TNBC.
Keywords: microRNA; breast cancer; triple negative
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
D'Ippolito, E.; Iorio, M.V. MicroRNAs and Triple Negative Breast Cancer. Int. J. Mol. Sci. 2013, 14, 22202-22220.
D'Ippolito E, Iorio MV. MicroRNAs and Triple Negative Breast Cancer. International Journal of Molecular Sciences. 2013; 14(11):22202-22220.
D'Ippolito, Elvira; Iorio, Marilena V. 2013. "MicroRNAs and Triple Negative Breast Cancer." Int. J. Mol. Sci. 14, no. 11: 22202-22220.